Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients

Neoplasma

Volumn 47, Issue 1, 2000, Pages 8-14

  Niewiadomska, H ^a   Mirowski, M ^a   Stempien M ^c   Blonski J Z ^c   Czyz, W ^c   Switalska J ^c   Matyga, E ^c   Hanausek, M ^b   Wierzbicki, R ^c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE

Author keywords

c erbB2; EGFR and breast cancer; p53; p65 oncofetal protein

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; ONCOFETAL ANTIGEN; POLYCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; BREAST CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0034024332     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ALLRED, D.C., CLARK, G.M., MOLINA, R., TANDOM, A.K., SCHNITT, S.J., GILCHRIST, K.W., OSBORNE, C.K., TORMEY, D.C., MCGUIRE, W.I.: Overexpression of HER2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathol., 23, 1992, 974-979.
2. ALLRED, D.C., CLARK, M.G., ELLEDGE, R., FUGUA, S.A.W., BROWN, R.W., CHAMNESS, G.C., OSBORN, C.K., MCGUIRE, W.L.: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85, 1993, 200-206.
3. ANDERSEN, T.I., HOLM, R., NESLAND, J.M., HEIMDAI, K.R., OTTESTAD, L., BORRENSEN, A.L.: Prognostic significance of p53 alteration in breast carcinoma. Br.J. Cancer, 68, 1993, 540-548.
4. BACUS, S.S., CHIN, D.M., STERN, R.K., OTRIZ, R., RUBY, S.G., WEINBERG, D.S.: HER2/neu oncogene expression and proliferation in breast cancers. Am. J. Pathol., 137, 1990, 103-111.
5. BARBARESCHI, M., LEONARDI, E., MAURI, F.A., SERIO, G., PALMA, P.D.: P53 and c-erbB2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am. J. Clin. Pathol., 98, 1992, 408-418.
6. BARNES, D.M., HANBY, A.M., GILLETT, C.E., MOHAMMED, S., HODGSON, S., BOBROW, E.G., LEIGH, I.M., PURKINS, T., MACGEOCH, C., SPURR, N.K.: Abnormal expression of wild type p53 protein in normal cells of a cancer family patients. Lancet, 340, 1992, 259-263.
7. BATTAGLIA, F., SCAMBIA, G., ROSSI, S., PANICI, P.B., BELLANTONE, R., POLIZZI, G., QUERZOLI, P., NEGRINI, R., IACOBELLI, S., CRUCTTTI, F., MANCUSO, S.: Epidermal growth factor receptor in human breast cancer: Correlation with steroid hormone receptors and axillary lymph node involvement. Eur. J. Clin. Oncol., 24, 1988, 1685-1691.
8. BOLLA, M., CHEDIN, M., COLONNA, M., MARRON, J., ROSTAING-PUISSANT, B., CHAMBAZ E.: Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur. J. Cancer, 28A, 1992, 1052-1054.
9. CHARPIN, C., DEVICTOR, B., BONNIER, P., ANDRAC, E., LAVAUT, M.N., ALLASIA, C., PIANA, L.: Epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br. J. Cancer, 66, 1992, 970-976.
10. GASPARINI, G., GULLICK, W.J., BEVILACQUA, P., SAINSBURY, J.R.C., MELI, S., BORACCHI, P., TESTOLIN, A., LAMALFA, G., POZZA, F.: Human breast cancer: Prognostic significance of the c-erbB2 oncoprotein compared with epidermal growth factor receptor. J. Clin. Oncol., 10, 1992, 686-695.
11. HARTMAN, L.C., INGLE, J.N., WOLD, L.E., FARR, G.H., GRILL, J.P., SU, J.Q., MAIHLE, N.J., KROOK, J.E., WITZING,T.E., ROCHE, P.C.: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer, 74, 1994, 2956 2963.
12. HORAK, E., SMITH, K., BROMLEY, L., LEJEUNE, S., GREENALL, M., LANE, D., HARRIS, A.L.: Mutant p53, EGF receptor and erbB2 expression in human breast cancer. Oncogene, 6, 1991, 2277-2284.
13. HORIGUCHI, J., IINO, Y., TAKEI, H., YOKOE, T., ISHIDA, T., MORISHITA, Y.: Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast cancer. Oncology, 51, 1994, 47-51.
14. HSU, S.M., RAINE, L., FANGER, H.: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29, 1981, 577-580.
15. JACQUEMIER, J., MOLES, J.P., PENAULT-LLORCA, F., ADLLAIDE, J., TORRENTE, M., VIENS, P., BIRNBAUM, D., THEILLET, C.: P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results. Br. J. Cancer , 69, 1994, 846-852.
16. JARDINES, L., WEISS, M., FOWBLE, B., GREENE, M.: Neu (c-erbB2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology, 61, 1993, 268-282.
17. KLIJN, J.G., BERNS, J.J., SCHNITZ, P.M.: The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: A review on 5232 patients. Endocr. Rev., 3, 1992, 13.
18. KOENDERS, P.G., BEEX, L.W.,KIENHUIS, C.B., KLOPPENBORG, P.W., BENRAAD, T.J.: Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study. Breast Cancer Res. Treat., 25, 1993, 21-27.
19. LIPPONEN, H.J., AALTOMAA, S., SYRJANEN, K.: c-erbB2 oncogene related to p53 expression, cell proliferation and prognosis on breast cancer. Anticancer Res., 13, 1993, 1147-1151.
20. MIROWSKI, M., WALASZEK, Z., SHERMAN, U., HANAUSEK, M.: Comparative structural analysis of human and rat 65 kDa tumor-associated phosphoproteins. Int. J. Biochem., 25, 1993, 1865-1871.
21. MIROWSKI, M., KLIJANIENKO, J., WANG, S., VIELH, P., WALASZEK, Z., HANAUSEK, M.: Serological and immunohistochemical detection of a 65-kDa oncofetal protein in breast cancer. Eur. J. Cancer, 30A, 1994, 1108-1113.
22. MIROWSKI, M., WALASZEK, Z., HANAUSEK, M.: Presence in bovine fetal serum of the protein antigenically related to p65-tumor associated antigen: Its isolation and polyclonal anti-body production. Neoplasma, 43, 1996, 83-88.
23. MIROWSKI, M., BŁOŃSKI, J.Z., NIEWIADOMSKA, H., OLBORSKI, B., WALASZEK, Z., HANAUSEK, M., WOZNIAK, L.: Immunohistochemical study of 65-kDa oncofetal protein expression in breast cancer. The breast, 6, 1997, 284-290.
24. MIROWSKI, M., RÓŻALSKI, M., KRAJEWSKA, U., HANAUSEK, M., WIERZBICKI, R.: Expression of a 65-kDa oncofetal protein in experimental hepatoma after anticancer therapy. Neoplasma, 44, 1997, 85-89.
25. NIEWIADOMSKA, H., MIROWSKI, M., SIEMPIEŃ, M., BLOŃSKI, J., HANAUSEK, M.: Clinical evaluation of the usefulness of polyclonal and monoclonal antibodies raised against p65 protein in immunohistochemical diagnosis of breast cancer: A comparative study. Biomed. Lett., 54, 1996, 223-231.
26. NIEWIADOMSKA, H., MIROWSKI, M., BARTKOWIAK, J., STEMPIEŃ M., BLOŃSKI , J.Z., WALASZEK, Z., HANAUSEK, M., WIERZBICKI, R.: Estrogen/progesterone receptors and a 65 kDa tumor-associated phosphoprotein (p65) expression in breast cancer patients. Biomed. Lett., 56, 1997, 91-99.
27. NIEWIADOMSKA, H., MIROWSKI, M., STEMPIEŃ, M., OLBORSKI, B., BLOŃSKI, J., HANAUSEK, M., WIERZBICKI, R.: A 65 kDa oncofetal protein (p65), proliferating cell nuclear antigen (PCNA) and Ki 67 expression in breast cancer patients. Neoplasma, 45, 1998, 216-222.
28. TETU, B., BRISSON, J.: Prognostic significance of HER2/neu oncoprotein expression in node-positive breast cancer. Cancer, 73, 1944, 2359-2365.
29. TOI, M., HAMADA, Y., NAKAMURA, Y., MUKAIDA, H., SUEHIRO, S., WADA, T., TOGE, T., NIIMOTO, M.: Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in breast cancer tisssues: Relationship to estrogen receptor and lymphatic invasion. Int. J. Cancer, 43, 1989, 220-225.
30. TSUDA, H., TSUGANE, S., FUKUTOMI, T., YAMAMOTO, H., HIROHASHI, S.: Prognostic factors for recurrent breast cancer: Univariate and multivariate analyses including histologic grade and amplification of the c-erbB2 protooncogene. Jpn. J. Clin. Oncol., 22, 1992, 244-249.
31. WANG, S., MIROWSKI, M., SHERMAN, U., WALASZEK, Z., HANAUSEK, M.: Monoclonal antibodies against a 65-kDa tumor-associated phosphoprotein: Development and use in cancer detection. Hybridoma, 12, 1993, 167-176.
32. Yoo, K.Y., TAJIMA, K., MIURA, S., YOSHIDA, M., MURAI, H., KUROISHI,T., LEE, Y., RISCH, H., DUBROV, R.: A hospital-based case-control study of breast cancer risk factors by estrogen and progesterone receptor status. Cancer Causes Control, 4, 1933, 39-44.